Skip to main content
Top
Published in: Comparative Hepatology 1/2010

Open Access 01-12-2010 | Research

Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours

Authors: Renee GHM van Sprundel, Ted SGAM van den Ingh, Valeer J Desmet, Azeam Katoonizadeh, Louis C Penning, Jan Rothuizen, Tania Roskams, Bart Spee

Published in: Comparative Hepatology | Issue 1/2010

Login to get access

Abstract

Background

The expression of Keratin 19 (K19) was reported in a subset of hepatocellular carcinomas (HCCs). K19 positive HCCs are associated with an increased malignancy compared to K19 negative HCCs. No suitable mouse models exist for this subtype of HCC, nor is the incidence of K19 expression in hepatocellular neoplasia in model animals known. Therefore, we compared the occurrence and tumour behaviour of K19 positive hepatocellular neoplasias in dog and man.

Results

The expression of hepatocellular differentiation (HepPar-1), biliary/progenitor cell (K7, K19), and malignancy (glypican-3) markers was semi-quantitatively assessed by immunohistochemistry. The histological grade of tumour differentiation was determined according to a modified classification of Edmondson and Steiner; the staging included intrahepatic, lymph node or distant metastases. Four of the 34 canine hepatocellular neoplasias showed K19 positivity (12%), of which two co-expressed K7. K19 positive tumours did not express HepPar-1, despite the histological evidence of a hepatocellular origin. Like in human HCC, all K19 positive hepatocellular neoplasias were glypican-3 positive and histologically poorly differentiated and revealed intra- or extrahepatic metastases whereas K19 negative hepatocellular neoplasias did not.

Conclusions

K19 positive hepatocellular neoplasias are highly comparable to man and occur in 12% of canine hepatocellular tumours and are associated with a poorly differentiated histology and aggressive tumour behaviour.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP: Liver stem cells and hepatocellular carcinoma. Hepatology. 2009, 49: 318-329. 10.1002/hep.22704.PubMedCentralCrossRefPubMed Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP: Liver stem cells and hepatocellular carcinoma. Hepatology. 2009, 49: 318-329. 10.1002/hep.22704.PubMedCentralCrossRefPubMed
2.
go back to reference Roskams TA, Libbrecht L, Desmet VJ: Progenitor cells in diseased human liver. Semin Liver Dis. 2003, 23: 385-396. 10.1055/s-2004-815564.CrossRefPubMed Roskams TA, Libbrecht L, Desmet VJ: Progenitor cells in diseased human liver. Semin Liver Dis. 2003, 23: 385-396. 10.1055/s-2004-815564.CrossRefPubMed
3.
go back to reference Forns X, Sanchez Tapias JM, Pares A, Llovet JM, Bruix J, Rodes J: Expected developments in hepatology. Best Pract Res Clin Gastroenterol. 2002, 16: 957-970. 10.1053/bega.2002.0341.CrossRefPubMed Forns X, Sanchez Tapias JM, Pares A, Llovet JM, Bruix J, Rodes J: Expected developments in hepatology. Best Pract Res Clin Gastroenterol. 2002, 16: 957-970. 10.1053/bega.2002.0341.CrossRefPubMed
4.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001, 94: 153-156. 10.1002/ijc.1440.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001, 94: 153-156. 10.1002/ijc.1440.CrossRefPubMed
5.
go back to reference Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K, Yamasaki S: Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998, 28: 1241-1246. 10.1002/hep.510280511.CrossRefPubMed Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K, Yamasaki S: Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998, 28: 1241-1246. 10.1002/hep.510280511.CrossRefPubMed
6.
go back to reference Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003, 38: 200-207. 10.1016/S0168-8278(02)00360-4.CrossRefPubMed Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003, 38: 200-207. 10.1016/S0168-8278(02)00360-4.CrossRefPubMed
7.
go back to reference Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Makuuchi M: Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996, 83: 1219-1222. 10.1002/bjs.1800830913.CrossRefPubMed Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Makuuchi M: Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996, 83: 1219-1222. 10.1002/bjs.1800830913.CrossRefPubMed
8.
go back to reference Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF: Long-term outcome of resection of large hepatocellular carcinoma. Br J Surg. 2006, 93: 600-606. 10.1002/bjs.5335.CrossRefPubMed Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF: Long-term outcome of resection of large hepatocellular carcinoma. Br J Surg. 2006, 93: 600-606. 10.1002/bjs.5335.CrossRefPubMed
9.
go back to reference Lai YS, Thung SN, Gerber MA, Chen ML, Schaffner F: Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med. 1989, 113: 134-138.PubMed Lai YS, Thung SN, Gerber MA, Chen ML, Schaffner F: Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med. 1989, 113: 134-138.PubMed
10.
go back to reference Van Eyken PL, Sciot R, Van Damme B, De Wolf-Peeters C, Desmet VJ: Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepatocytes, bile ducts and acinar gradient. Virchows Arch A Pathol Anat Histopathol. 1987, 412: 63-72. 10.1007/BF00750732.CrossRefPubMed Van Eyken PL, Sciot R, Van Damme B, De Wolf-Peeters C, Desmet VJ: Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepatocytes, bile ducts and acinar gradient. Virchows Arch A Pathol Anat Histopathol. 1987, 412: 63-72. 10.1007/BF00750732.CrossRefPubMed
11.
go back to reference Roskams T, De Vos R, van Eyken P, Myazaki H, Van Damme B, Desmet V: Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol. 1998, 29: 455-463. 10.1016/S0168-8278(98)80065-2.CrossRefPubMed Roskams T, De Vos R, van Eyken P, Myazaki H, Van Damme B, Desmet V: Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol. 1998, 29: 455-463. 10.1016/S0168-8278(98)80065-2.CrossRefPubMed
12.
go back to reference Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006, 49: 138-151. 10.1111/j.1365-2559.2006.02468.x.CrossRefPubMed Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T: The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006, 49: 138-151. 10.1111/j.1365-2559.2006.02468.x.CrossRefPubMed
13.
go back to reference Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K: Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003, 94: 851-857. 10.1111/j.1349-7006.2003.tb01366.x.CrossRefPubMed Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K: Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003, 94: 851-857. 10.1111/j.1349-7006.2003.tb01366.x.CrossRefPubMed
14.
go back to reference van Eyken P, Sciot R, Paterson A, Callea F, Kew MC, Desmet VJ: Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol. 1988, 19: 562-568. 10.1016/S0046-8177(88)80205-3.CrossRefPubMed van Eyken P, Sciot R, Paterson A, Callea F, Kew MC, Desmet VJ: Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol. 1988, 19: 562-568. 10.1016/S0046-8177(88)80205-3.CrossRefPubMed
15.
go back to reference Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY: Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996, 149: 1167-1175.PubMedCentralPubMed Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY: Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996, 149: 1167-1175.PubMedCentralPubMed
16.
go back to reference Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP: Prognostic molecular markers in hepatocellular carcinoma: A systematic review. Eur J Cancer. 2007 Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP: Prognostic molecular markers in hepatocellular carcinoma: A systematic review. Eur J Cancer. 2007
17.
go back to reference Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, Kawano N, Morioka Y: Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990, 211: 28-33. 10.1097/00000658-199001000-00005.PubMedCentralCrossRefPubMed Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, Kawano N, Morioka Y: Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990, 211: 28-33. 10.1097/00000658-199001000-00005.PubMedCentralCrossRefPubMed
18.
go back to reference Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, Giulini SM: Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006, 243: 229-235. 10.1097/01.sla.0000197706.21803.a1.PubMedCentralCrossRefPubMed Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, Giulini SM: Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006, 243: 229-235. 10.1097/01.sla.0000197706.21803.a1.PubMedCentralCrossRefPubMed
19.
go back to reference Grozdanov PN, Yovchev MI, Dabeva MD: The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006, 86: 1272-1284. 10.1038/labinvest.3700479.CrossRefPubMed Grozdanov PN, Yovchev MI, Dabeva MD: The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006, 86: 1272-1284. 10.1038/labinvest.3700479.CrossRefPubMed
20.
go back to reference Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa CA, Rullier A, Cubel G, Couchy G, Imbeaud S, et al: Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007, 46: 740-748. 10.1002/hep.21743.CrossRefPubMed Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa CA, Rullier A, Cubel G, Couchy G, Imbeaud S, et al: Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007, 46: 740-748. 10.1002/hep.21743.CrossRefPubMed
21.
go back to reference Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L, Tornillo L, Vecchione R, Roncalli M: Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007, 45: 725-734. 10.1002/hep.21531.CrossRefPubMed Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L, Tornillo L, Vecchione R, Roncalli M: Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007, 45: 725-734. 10.1002/hep.21531.CrossRefPubMed
22.
23.
24.
go back to reference Sell S: Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol. 2002, 13: 419-424. 10.1016/S1084952102001295.CrossRefPubMed Sell S: Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol. 2002, 13: 419-424. 10.1016/S1084952102001295.CrossRefPubMed
25.
go back to reference Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006, 12: 410-416. 10.1038/nm1377.CrossRefPubMed Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006, 12: 410-416. 10.1038/nm1377.CrossRefPubMed
26.
go back to reference Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, Lee JJ, Park C: High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest. 2008, 88: 144-152. 10.1038/labinvest.3700710.CrossRefPubMed Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, Lee JJ, Park C: High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest. 2008, 88: 144-152. 10.1038/labinvest.3700710.CrossRefPubMed
27.
go back to reference Sell S: The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. Int J Dev Biol. 1993, 37: 189-201.PubMed Sell S: The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. Int J Dev Biol. 1993, 37: 189-201.PubMed
28.
go back to reference Libbrecht L, Severi T, Cassiman D, Borght Vander S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T: Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006, 30: 1405-1411. 10.1097/01.pas.0000213323.97294.9a.CrossRefPubMed Libbrecht L, Severi T, Cassiman D, Borght Vander S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T: Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006, 30: 1405-1411. 10.1097/01.pas.0000213323.97294.9a.CrossRefPubMed
29.
go back to reference Kitao S, Yamada T, Ishikawa T, Madarame H, Furuichi M, Neo S, Tsuchiya R, Kobayashi K: Alpha-fetoprotein in serum and tumor tissues in dogs with hepatocellular carcinoma. J Vet Diagn Invest. 2006, 18: 291-295.CrossRefPubMed Kitao S, Yamada T, Ishikawa T, Madarame H, Furuichi M, Neo S, Tsuchiya R, Kobayashi K: Alpha-fetoprotein in serum and tumor tissues in dogs with hepatocellular carcinoma. J Vet Diagn Invest. 2006, 18: 291-295.CrossRefPubMed
30.
go back to reference Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001, 35: 421-430. 10.1016/S0168-8278(01)00130-1.CrossRefPubMed Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001, 35: 421-430. 10.1016/S0168-8278(01)00130-1.CrossRefPubMed
31.
go back to reference Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, et al: From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2004, 3: 73-81.CrossRefPubMed Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, et al: From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2004, 3: 73-81.CrossRefPubMed
32.
go back to reference Dobashi N, Fujita J, Murota M, Ohtsuki Y, Bandoh S, Ueda Y, Dohmoto K, Hojo S, Nishioka M, Ishida T, Takahara J: Binding of recombinant human cytokeratin 19 to laminin: a possible role in interaction between intermediate filament derived from epithelial cells and extracellular matrixes. Cell Struct Funct. 2000, 25: 171-175. 10.1247/csf.25.171.CrossRefPubMed Dobashi N, Fujita J, Murota M, Ohtsuki Y, Bandoh S, Ueda Y, Dohmoto K, Hojo S, Nishioka M, Ishida T, Takahara J: Binding of recombinant human cytokeratin 19 to laminin: a possible role in interaction between intermediate filament derived from epithelial cells and extracellular matrixes. Cell Struct Funct. 2000, 25: 171-175. 10.1247/csf.25.171.CrossRefPubMed
33.
go back to reference Chu YW, Runyan RB, Oshima RG, Hendrix MJ: Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA. 1993, 90: 4261-4265. 10.1073/pnas.90.9.4261.PubMedCentralCrossRefPubMed Chu YW, Runyan RB, Oshima RG, Hendrix MJ: Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA. 1993, 90: 4261-4265. 10.1073/pnas.90.9.4261.PubMedCentralCrossRefPubMed
34.
go back to reference Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, Nishiguchi S: Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer. 2003, 88: 1894-1899. 10.1038/sj.bjc.6601026.PubMedCentralCrossRefPubMed Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, Nishiguchi S: Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer. 2003, 88: 1894-1899. 10.1038/sj.bjc.6601026.PubMedCentralCrossRefPubMed
35.
go back to reference Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, Yamaji Y, Ohtsuki Y, Dobashi N, Ishida T, Takahara J: The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer. 2001, 91: 468-473. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1082>3.0.CO;2-T.CrossRefPubMed Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, Yamaji Y, Ohtsuki Y, Dobashi N, Ishida T, Takahara J: The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer. 2001, 91: 468-473. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1082>3.0.CO;2-T.CrossRefPubMed
36.
go back to reference Wu F, Fujita J, Murota M, Li JQ, Ishida T, Nishioka M, Imaida Y, Kuriyama S: CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. Int J Oncol. 2002, 21: 441-445.PubMed Wu F, Fujita J, Murota M, Li JQ, Ishida T, Nishioka M, Imaida Y, Kuriyama S: CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. Int J Oncol. 2002, 21: 441-445.PubMed
37.
go back to reference Iyer A, Robert ME, Bifulco CB, Salem RR, Jain D: Different cytokeratin and neuronal cell adhesion molecule staining patterns in focal nodular hyperplasia and hepatic adenoma and their significance. Hum Pathol. 2008, 39: 1370-1377. 10.1016/j.humpath.2008.01.015.PubMedCentralCrossRefPubMed Iyer A, Robert ME, Bifulco CB, Salem RR, Jain D: Different cytokeratin and neuronal cell adhesion molecule staining patterns in focal nodular hyperplasia and hepatic adenoma and their significance. Hum Pathol. 2008, 39: 1370-1377. 10.1016/j.humpath.2008.01.015.PubMedCentralCrossRefPubMed
38.
go back to reference Shafizadeh N, Ferrell LD, Kakar S: Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008, 21: 1011-1018. 10.1038/modpathol.2008.85.CrossRefPubMed Shafizadeh N, Ferrell LD, Kakar S: Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008, 21: 1011-1018. 10.1038/modpathol.2008.85.CrossRefPubMed
39.
go back to reference Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M: Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003, 94: 259-262. 10.1111/j.1349-7006.2003.tb01430.x.CrossRefPubMed Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M: Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003, 94: 259-262. 10.1111/j.1349-7006.2003.tb01430.x.CrossRefPubMed
40.
go back to reference Vauthey JN, Lauwers GY: Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest?. J Hepatol. 2003, 38: 237-239. 10.1016/S0168-8278(02)00407-5.CrossRefPubMed Vauthey JN, Lauwers GY: Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest?. J Hepatol. 2003, 38: 237-239. 10.1016/S0168-8278(02)00407-5.CrossRefPubMed
41.
go back to reference Patnaik AK, Newman SJ, Scase T, Erlandson RA, Antonescu C, Craft D, Bergman PJ: Canine hepatic neuroendocrine carcinoma: an immunohistochemical and electron microscopic study. Vet Pathol. 2005, 42: 140-146. 10.1354/vp.42-2-140.CrossRefPubMed Patnaik AK, Newman SJ, Scase T, Erlandson RA, Antonescu C, Craft D, Bergman PJ: Canine hepatic neuroendocrine carcinoma: an immunohistochemical and electron microscopic study. Vet Pathol. 2005, 42: 140-146. 10.1354/vp.42-2-140.CrossRefPubMed
42.
go back to reference Trigo FJ, Thompson H, Breeze RG, Nash AS: The pathology of liver tumours in the dog. J Comp Pathol. 1982, 92: 21-39. 10.1016/0021-9975(82)90040-8.CrossRefPubMed Trigo FJ, Thompson H, Breeze RG, Nash AS: The pathology of liver tumours in the dog. J Comp Pathol. 1982, 92: 21-39. 10.1016/0021-9975(82)90040-8.CrossRefPubMed
43.
go back to reference Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P: Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006, 43: 515-524. 10.1002/hep.21068.CrossRefPubMed Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P: Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006, 43: 515-524. 10.1002/hep.21068.CrossRefPubMed
44.
go back to reference Komuta M, Spee B, Borght Vander S, De Vos R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, Desmet VJ, Kojiro M, Roskams T: Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008, 47: 1544-1556. 10.1002/hep.22238.CrossRefPubMed Komuta M, Spee B, Borght Vander S, De Vos R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, Desmet VJ, Kojiro M, Roskams T: Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008, 47: 1544-1556. 10.1002/hep.22238.CrossRefPubMed
Metadata
Title
Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours
Authors
Renee GHM van Sprundel
Ted SGAM van den Ingh
Valeer J Desmet
Azeam Katoonizadeh
Louis C Penning
Jan Rothuizen
Tania Roskams
Bart Spee
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Comparative Hepatology / Issue 1/2010
Electronic ISSN: 1476-5926
DOI
https://doi.org/10.1186/1476-5926-9-4

Other articles of this Issue 1/2010

Comparative Hepatology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.